Cardiac effects of hyperprolactinemiatherapy withdopamine agonists

Ю. В. Давыдова, А. Ю. Лиманская, Т. В. Волошина, Л. Е. Костромина

Abstract


A number of publications of the 1990s found an association between the development of disease of the heart valves and the use of dopamine agonists in patients receiving treatment for Parkinson’s disease. Therefore, it became necessary to investigate the possible risks of valve disease in patients with hyperprolactinemia receiving treatment with dopamine agonists, in order to improve the recommendations.


Keywords


hyperprolactinemia; dopamine agonists; Parkinson’s disease; cabergoline

References


Ling L.H, Ahlskog J.E., MungerT.M., Limper A.H., Oh J.K. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson’s disease. Mayo Clin Proc 1999. 74 : 371-375.

Van Camp G., Flamez A., Cosyns B. et al. Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004. 363: 1179-1183.

Antonini A., Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet 2007. Neurol. 6: 826-829.

Flowers C.M., Racoosin J.A., Lu S.L., Beitz J.G. The U.S. Food and Drug Administration’s Registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc. 2003 78: 730-731.

FDA Public Health Advisory: pergolide. March 29, 2007. http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051192.htm

Andersohn F., Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot- and nonergot-derived dopamine agonists. Mov. Disord. 2009. 24: 129-133.

Nebigil C.G., Choi D.S., Dierich A. et al. Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci USA. 2000. 97: 9508-9513.

Lin Z., Walther D., Yu X.Y., Drgon T., Uhl G.R. The human serotonin receptor 2B: coding region polymorphisms andassociation with vulnerability to illegal drug abuse. Pharmacogenetics. 2004. 14: 805-811.

Kars M. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol. 2008.159: 363-367.

Bogazzi F., Manetti L., Raffaelli V. et al. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest. 2008. 31: 1119-1123.

Klibanski A. Dopamine agonist therapy in prolactinomas: when can treatment be discontinued? J Clin Endocrinol Metab. 2009. 94: 2247-2249.

Colao A., Galderisi M., Di Sarno A. et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab. 2008. 93: 3777-3784.

Heart Valve Disease among Patients with Hyperprolactinemia: A Nationwide Population-Based Cohort Study.J. Clin. Endocrinol. Metab. 2012. 97: 1629-1634.

Molitch M.E. The cabergoline-resistant prolactinoma patient: new challenges. J Clin Endocrinol Metab. 2008. 93:4 643-4645.

Trifirò G. et al. Risk of Cardiac Valve Regurgitation with Dopamine Agonist use in Parkinson’s Disease and Hyperprolactinaemia: A Multi-Country, Nested Case-Control Study. Drug Safety:1 February 2012, Volume 35, Issue 2, 159-171.

Cosyns B., Droogmans S., Rosenhek R., Lancellotti P. Drug-induced valvular heart disease Heart. 2012 Aug. 8.


GOST Style Citations


Ling L.H, Ahlskog J.E., MungerT.M., Limper A.H., Oh J.K. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson’s disease. Mayo Clin Proc 1999. 74 : 371-375.

Van Camp G., Flamez A., Cosyns B. et al. Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004. 363: 1179-1183.

Antonini A., Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet 2007. Neurol. 6: 826-829.

Flowers C.M., Racoosin J.A., Lu S.L., Beitz J.G. The U.S. Food and Drug Administration’s Registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc. 2003 78: 730-731.

FDA Public Health Advisory: pergolide. March 29, 2007. http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051192.htm

Andersohn F., Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot- and nonergot-derived dopamine agonists. Mov. Disord. 2009. 24: 129-133.

Nebigil C.G., Choi D.S., Dierich A. et al. Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci USA. 2000. 97: 9508-9513.

Lin Z., Walther D., Yu X.Y., Drgon T., Uhl G.R. The human serotonin receptor 2B: coding region polymorphisms andassociation with vulnerability to illegal drug abuse. Pharmacogenetics. 2004. 14: 805-811.

Kars M. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol. 2008.159: 363-367.

Bogazzi F., Manetti L., Raffaelli V. et al. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest. 2008. 31: 1119-1123.

Klibanski A. Dopamine agonist therapy in prolactinomas: when can treatment be discontinued? J Clin Endocrinol Metab. 2009. 94: 2247-2249.

Colao A., Galderisi M., Di Sarno A. et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab. 2008. 93: 3777-3784.

Heart Valve Disease among Patients with Hyperprolactinemia: A Nationwide Population-Based Cohort Study.J. Clin. Endocrinol. Metab. 2012. 97: 1629-1634.

Molitch M.E. The cabergoline-resistant prolactinoma patient: new challenges. J Clin Endocrinol Metab. 2008. 93:4 643-4645.

Trifirò G. et al. Risk of Cardiac Valve Regurgitation with Dopamine Agonist use in Parkinson’s Disease and Hyperprolactinaemia: A Multi-Country, Nested Case-Control Study. Drug Safety:1 February 2012, Volume 35, Issue 2, 159-171.

Cosyns B., Droogmans S., Rosenhek R., Lancellotti P. Drug-induced valvular heart disease Heart. 2012 Aug. 8.





DOI: http://dx.doi.org/10.18370/2309-4117.2012.6.50-54

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2411-1295 (Online), ISSN 2309-4117 (Print)